4.7 Review

American Society of Clinical Oncology Clinical Practice Guidelines: Formal Systematic Review-Based Consensus Methodology

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 30, Issue 25, Pages 3136-3140

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2012.42.0489

Keywords

-

Categories

Ask authors/readers for more resources

The American Society of Clinical Oncology (ASCO) guidelines program employs a systematic review-based methodology to produce evidence-based guidelines. This is consistent with the stance of the Institute of Medicine on guideline development, which is that high-quality evidence syntheses form the basis for recommendation development. In the absence of high-quality evidence, recommendation development becomes more complex. One option is to provide no recommendations or withdraw a guideline topic. However, it is often the areas of greatest uncertainty in which the evidentiary base is incomplete, and thus, guidelines are needed most. To provide recommendations in such circumstances, an explicit methodology is needed to ensure that a credible process is undertaken, and rigorous, reliable advice is provided. In 2010, the ASCO Board of Directors approved development of guideline recommendations using consensus methodology. A modified Delphi approach to recommendation development, based on the best available data identified in a systematic review, was piloted with an ASCO guideline. Consensus was achieved through the rating of a series of recommendations by a large group of clinicians, including academic and community-based content and methodology experts. A prespecified threshold of agreement was determined to indicate when consensus was achieved. Consensus was defined as agreement by >= 75% of raters. The formal consensus methodology used by ASCO enabled development of guideline recommendations on a challenging clinical issue based on limited evidence using a rigorous, transparent, and explicit method. This methodology is proposed for development of future ASCO guidelines on topics for which limited evidence is available. J Clin Oncol 30: 3136-3140. (C) 2012 by American Society of Clinical Oncology

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Health Care Sciences & Services

Building Palliative Care Capacity for Generalist Providers in the Community: Results From the Capaciti Pilot Education Program

Hsien Seow, Daryl Bainbridge, Kelli Stajduhar, Denise Marshall, Michelle Howard, Melissa Brouwers, Doris Barwich, Fred Burge, Mary Lou Kelley

Summary: CAPACITI is a virtual training program aimed at helping primary care providers offer early palliative care. An evaluation study found that CAPACITI can improve provider confidence in core competencies and potentially enhance palliative care capacity in primary care teams.

AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE (2023)

Editorial Material Oncology

Risk Model Development and Validation in Clinical Oncology: Lessons Learned

Gary H. Lyman, Pavlos Msaouel, Nicole M. Kuderer

Summary: This article summarizes key considerations related to risk modeling in clinical oncology, including data quality, missing data, sample size estimation, and variable selection. The importance of rigorous internal validation and careful examination of model stability and quality is emphasized.

CANCER INVESTIGATION (2023)

Article Oncology

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice

Funda Meric-Bernstam, James M. Ford, Peter J. O'Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin, Roisin E. O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gary H. Lyman, James Tricoli, David Patton, Stanley R. Hamilton, Robert J. Gray, Douglas S. Hawkins, Bhanumati Ramineni, Keith T. Flaherty, Petros Grivas, Timothy A. Yap, Jordan Berlin, James H. Doroshow, Lyndsay N. Harris, Jeffrey A. Moscow

Summary: In the past decade, there have been multiple trials to determine the effectiveness of treating cancer based on specific genomic alterations. However, most patients do not respond to single-agent therapies targeting a single alteration, and drug resistance often develops. To address this, the NCI has developed NCI-ComboMATCH, a study to explore genomically-directed combination therapies and overcome drug resistance.

CLINICAL CANCER RESEARCH (2023)

Review Medical Laboratory Technology

Choosing which in-hospital laboratory tests to target for intervention: a scoping review

Eyal Podolsky, Natasha Hudek, Christopher McCudden, Justin Presseau, Sezgi Yanikomeroglu, Melissa Brouwers, Jamie C. C. Brehaut

Summary: This scoping review investigates the factors and processes that developers report using to inform decisions about what tests to target for practice improvement. From 114 eligible studies, 30 factors related to test choice and nine processes used to inform decisions were identified.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2023)

Correction Surgery

AGREE-S: AGREE II extension for surgical interventions: appraisal instrument (vol 36, pg 5547, 2022)

Stavros A. Antoniou, Ivan D. Florez, Sheraz Markar, Patricia Logullo, Manuel Lopez-Cano, Gianfranco Silecchia, George A. Antoniou, Sofia Tsokani, Dimitrios Mavridis, Melissa Brouwers

SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES (2023)

Article Oncology

Grade 4 Neutropenia Frequency as a Binary Risk Predictor for Adverse Clinical Consequences of Chemotherapy-Induced Neutropenia: A Meta-analysis

Ramon Mohanlal, Stephan Ogenstad, Gary H. Lyman, Lan Huang, Douglas W. Blayney

Summary: Neutropenia caused by myelosuppressive cancer chemotherapy is a significant toxicity, and grade 4 neutropenia (Gr4N) is a measure of its severity. Through a meta-analysis, we found that the incidence of Gr4N is closely correlated with febrile neutropenia (FN), days of severe neutropenia (DSN), and nadir absolute neutrophil count (ANC), all of which are important predictors of morbidity. By setting a threshold of 65% for Gr4N, the risks of FN and DSN were below the levels for adverse CIN outcomes. Gr4N is highly predictive for adverse CIN outcomes, and a 65% threshold distinguishes between low and high risks for FN and other adverse CIN outcomes.

CANCER INVESTIGATION (2023)

Review Oncology

Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship

Maryam B. Lustberg, Nicole M. Kuderer, Aakash Desai, Cristiane Bergerot, Gary H. Lyman

Summary: Despite the lack of systematic efforts, this review provides a comprehensive analysis of the most common long-term and late adverse events associated with chemotherapy and other anticancer treatments. It discusses the underlying mechanisms, management strategies, and clinical practice guidelines for these adverse events. Additionally, it highlights the need for effective management of treatment-related events in oncology.

NATURE REVIEWS CLINICAL ONCOLOGY (2023)

Article Oncology

Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021

Brian Bourbeau, Gary H. Lyman, Xiudong Jennifer Lei, Lee Jones, Jon Rosenthal, Mary May Kozlik, Kurt R. Oettel, Alfred Tinger, Ray Page

Summary: Biosimilars have increased in usage over the past 3 years, with utilization rates ranging from 51% to 80% depending on the specific biologic. Independent physician practices had higher utilization of biosimilars for certain biologics, while Medicaid plans and traditional Medicare had lower utilization rates compared to commercial health plans. The average cost per dose decreased by 24% to 41% for the studied biologics.

JCO ONCOLOGY PRACTICE (2023)

Article Oncology

ASCO Policy Statement on Biosimilar and Interchangeable Products in Oncology

Gladys Rodriguez, Joan Mancuso, Gary H. Lyman, Fatima Cardoso, Zeina Nahleh, Julie M. Vose, Julie R. Gralow, Michael Francisco, Shimere Sherwood

Summary: ASCO has taken steps to raise awareness about biosimilar products and published a statement in 2018 to provide guidance on their use in oncology. The FDA has approved a significant number of biosimilar products for use in the United States, including those for cancer treatment. The recent approval of interchangeable biosimilar products for various diseases has further expanded the market. This policy statement by ASCO proposes recommendations on value, interchangeability, clinician barriers, and patient education and access to guide their future activities.

JCO ONCOLOGY PRACTICE (2023)

Editorial Material Oncology

Perception, Cognition and Thought: Part V Entropy, the Arrow of Time and the Present

Gary H. Lyman, Christopher H. Lyman, Nicole M. Kuderer

CANCER INVESTIGATION (2023)

Editorial Material Oncology

Perception, Cognition and Thought: Part IV Consciousness, Awareness, and I

Gary H. Lyman, Christopher H. Lyman, Nicole M. Kuderer

CANCER INVESTIGATION (2023)

Editorial Material Oncology

Perception, Cognition and Thought: Part II Symbolic Processing and Language

Gary H. Lyman

CANCER INVESTIGATION (2023)

Editorial Material Oncology

Perception, Cognition and Thought: Part III: Reasoning, Judgement and Decision-Making

Gary H. Lyman, Nicole M. Kuderer

CANCER INVESTIGATION (2023)

Editorial Material Oncology

The Nature, Origin and Evolution of Life: Part I The Fundamental Logic and Organization of Life

Gary H. Lyman, Christopher H. Lyman, Nicole M. Kuderer

CANCER INVESTIGATION (2023)

No Data Available